‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent
Nature Reviews Clinical Oncology, Published online: 05 January 2024; doi:10.1038/s41571-023-00857-9The FDA approval of perioperative pembrolizumab, an approach that combines neoadjuvant and adjuvant therapy with this agent, for patients with early stage non-small-cell lung cancer (NSCLC) contradicts its own stated standard for combination therapies. Given the large population of patients with early stage NSCLC and the high costs of pembrolizumab, whether the adjuvant component provides incremental benefit is an important question.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Garth W. Strohbehn Bishal Gyawali Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer